Using L-carnitine to reduce pain and inflammation in rheumatoid arthritis
The Use of L-carnitine in Modulating Pain and Inflammation in Rheumatoid Arthritis Patients
This study is testing if L-carnitine can help reduce pain and inflammation in people with active rheumatoid arthritis who are already taking standard medications.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 46 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Tanta, Gharbia) |
| Trial ID | NCT05792527 on ClinicalTrials.gov |
What this trial studies
This study evaluates the efficacy and safety of L-carnitine in patients with active rheumatoid arthritis by targeting the Jak/STAT pathway and TGF-β1. It involves administering L-carnitine to participants who are already receiving conventional disease-modifying antirheumatic drugs (DMARDs). The study aims to determine if L-carnitine can improve symptoms and reduce inflammation associated with the condition. Participants will be monitored for changes in disease activity and any potential side effects.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 70 with active rheumatoid arthritis who are currently on conventional DMARDs.
Not a fit: Patients with significant comorbidities such as heart disease, diabetes, or those receiving biological DMARDs may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new option for managing pain and inflammation in rheumatoid arthritis patients.
How similar studies have performed: While the specific use of L-carnitine in this context is novel, similar studies targeting inflammatory pathways have shown promise in other conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2010 criteria (9) i.e., 28 joints disease activity score (DAS-28) \>2.6. * Patients receive the conventional DMARDs * Both sexes. * Age range between 18 and 70 years old. Exclusion Criteria: * Patients with heart disease (congestive heart failure, arrhythmia, hypertension, ischemic heart diseases), diabetes, active infection, other illness except rheumatoid arthritis. * Patients with renal and hepatic dysfunction. * Patients receiving biological DMARDs. * Patients receiving oral prednisolone greater than 15 mg/day. * Patients with hypersensitivity to study medications. * Patients using antioxidants. * Pregnant and lactating females.
Where this trial is running
Tanta, Gharbia
- Tanta university — Tanta, Gharbia, Egypt (Recruiting)
Study contacts
- Study coordinator: Abdallah A Eldisouky
- Email: PG_165476@pharm.tanta.edu.eg
- Phone: 201279142631
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.